vasopharm GmbH Announces Post Hoc Analyses of Clinical Trials in Traumatic Brain Injury

- Improved neurologic outcome in young adults (18-39 years) with Ronopterin infused early - Significantly less aggressive critical care with maintained renal function in young adults -

Related Keywords

Germany ,Glasgow ,Glasgow City ,United Kingdom ,Nostra ,Käten ,Austria ,Switzerland ,France ,Spain ,Harald Schmidt ,Kostenloser Wertpapierhandel ,John Stover ,Ulrich Walter ,Erich Schmutzhard ,University Of Innsbruck ,Drug Monitoring Committee ,Clinical Development Plan For Ronopterin ,Clinical Development Plan ,Medical University ,Chief Investigator ,Glasgow Outcome Scale ,Unfavorable Outcome ,Favorable Outcome ,Good Recovery ,Intensity Level ,Chief Medical Officer ,Traumatic Brain Injury ,Medical School ,Clinical Biochemistry ,Nitric Oxide Synthase ,Glasgow Outcome Score ,Full Analysis Set ,Glasgow Outcomes Scale ,Vasopharm ,Mbh ,Nnounces ,Most ,Analyses ,Linical ,Trials ,Traumatic ,Rain ,Injury ,